2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original Research
2013
Triple-negative breast cancer: molecular characterization and targeted therapies
Nicholson A, Bishop J, Lannin D, Killelea B, Guo X, Cha C, Dixon J. Triple-negative breast cancer: molecular characterization and targeted therapies. Breast Cancer Management 2013, 2: 417-430. DOI: 10.2217/bmt.13.40.Peer-Reviewed Original ResearchBreast cancerTriple-negative breast cancerAggressive breast cancerCancer Genome Atlas NetworkAggressive subtypeSingle therapyClinical trialsTherapeutic targetExtensive molecular characterizationMolecular alterationsIndividual cancersCancerTherapyMolecular targetsMolecular reviewMolecular characterizationRelated mutationsSubtypesTrials
2011
Breast Conservation Therapy for Ductal Carcinoma In Situ (DCIS): Is there a difference in Clinical-Pathologic Features and Long Term Outcomes in Occult, Mammographically-Detected Disease Compared with DCIS Presenting with Physical Findings?
Bai H, Lannin D, Higgins S, Motwani S, Hafty B, Goyal S, Wilson L, Evans S, Moran M. Breast Conservation Therapy for Ductal Carcinoma In Situ (DCIS): Is there a difference in Clinical-Pathologic Features and Long Term Outcomes in Occult, Mammographically-Detected Disease Compared with DCIS Presenting with Physical Findings? International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s245. DOI: 10.1016/j.ijrobp.2011.06.1716.Peer-Reviewed Original Research
2004
Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option?
Haffty B, Lannin D. Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option? European Journal Of Cancer 2004, 40: 1105-1108. PMID: 15110872, DOI: 10.1016/j.ejca.2004.01.032.Peer-Reviewed Original Research